A research team in the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine of the University of Hong Kong ...

Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator ...

Content by Health System. With Asthma Peak Week typically during the middle of September, now is a great time to learn the ...

New research from the University of Copenhagen shows that team sports are a highly effective and potentially life-extending form of exercise for patients with high blood pressure and COPD. Even after ...

ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates.

The BeLPT has high specificity for identifying chronic beryllium disease but poor sensitivity in distinguishing it from sarcoidosis.

Among women with asthma, elevated average fine particulate matter and nitrogen dioxide exposure over 48 months each raised ...

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although ...

Tyr Pharma (ATYR) announced topline results from the Phase 3 EFZO-FIT study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major ...

Discover the activity that boosts brain power, lung health, and social connection for seniors in their retirement years.

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.